NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 7 August 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Raju Reddy (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Present for all items
5. Paul Caulfield Items 1.1 to 5.2.2
6. Sarah Davis Items 6.1.1 to 6.2.2
7. Professor Sofia Dias Present for all items
8. Dr James Fotheringham Items 6.1.1 to 6.2.2
9. Dr Bushra Hasnie Items 5.1.1 to 5.2.2
10. Dr Robert Hodgson Present for all items
11. Dr Bernard Khoo Items 1.1 to 6.1.3
12. Dr Guy Makin Present for all items
13. Dr Philip Mallender Present for all items
14. Giles Monnickendam Present for all items
15. Dr Nathan Moore Present for all items
16. Carole Pitkeathley Present for all items
17. Dr Ben Searle Present for all items
18. Dr Will Sullivan Present for all items
19. Dr Zenas Yiu Present for all items
20. Sue Wen Leo (Observing) Items 1.1 to 4.2.2

NICE staff (key players) present

Ian Watson, Associate Director Items 1.1 to 4.2.2

Leena Issa, Project Manager Items 1.1 to 4.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Emma Douch, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5.1.1 to 6.2.2

Louise Jafferally, Project Manager Items 5.1.1 to 5.2.2

Adam Brooke, Heath Technology Assessment Adviser Items 5.1.1 to 6.2.2

Sam Slayen, Heath Technology Assessment Analyst Items 5.1.1 to 5.2.2

Cara Gibbons, Heath Technology Assessment Analyst Items 6.1.1 to 6.2.2

External assessment group representatives present

Nigel Armstrong, KSR Items 1.1 to 4.1.3

Venetia Qendri, KSR Items 1.1 to 4.1.3

Dr Janette Greenhalgh, LRiG Items 5.1.1 to 5.1.3

Sam Bryning, LRiG Items 5.1.1 to 5.1.3

Isaac Mackenzie, BMJ Items 6.1.1 to 6.1.3

Melina Vasileiou, BMJ Items 6.1.1 to 6.1.3

Clinical, Patient & NHS England experts present

Dr Alice Taylor, Haematology Consultant, Clinical Expert nominated by UK Haemophilia Centre Doctors’ Organisation Items 1.1 to 4.1.3

Dr Charles Hay, Professor of Haemostasis and Thrombosis at UKHCDO, Consultant Haematologist Director of the UK National Haemophilia Database, Clinical Expert nominated by Swedish Orphan Biovitrum Items 1.1 to 4.1.3

Clive Smith, Chair of the Board at The Haemophilia Society, Patient Expert nominated by The Haemophilia Society Items 1.1 to 4.1.3

Dr James Richardson, NHSE CDF Oncology Pharmacist Lead

Items 5.1.1 to 6.2.2

Peter Clark, CDF Clinical lead, NHSE Items 5.1.1 to 6.2.2

Dr Riyaz Shah, Consultant Medical Oncologist at Kent Oncology Centre, Clinical Expert, nominated by BTOG Items 5.1.1 to 5.1.3

Dr Toby Talbot, Consultant Clinical Oncologist at Royal Cornwall Hospital NHS Trust, Clinical Expert, nominated by MSD (company) Items 5.1.1 to 5.1.3 & Items 6.1.1 to 6.1.3

Dr Yvonne Summers, Clinical Director and Consultant Medical Oncologist, Clinical Expert, nominated by AstraZeneca (comparator) Items 5.1.1 to 5.1.3

Professor Mary O’Brien, Consultant Medical Oncologist at Royal Marsden Hospital, Clinical Expert, nominated by BTOG/NCRI/RCP/ACP/RCR Items 6.1.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Andrew Fox, Craig Cook, Professor David Meads, Dr Paula Parvulescu and Sophia Steer.

### News and announcements

* 1. The Chair welcomed new committee member Sue Wen Leo.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 3 July 2024.

### Appraisal of efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Swedish Orphan Biovitrum.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11106).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11106>

### Appraisal of pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11174).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Dr Ben Searle, and Dr Robert Hodgson.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11174>

### Appraisal of pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

* 1. Part 1 – Open session
     1. The Chair, Dr Raju Reddy, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10784/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Robert Hodgson, Will Sullivan, Dr Ben Searle.
  2. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10784/documents>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 4 September 2024 and will start promptly at 09:00am.